Quoin Pharmaceuticals Announces FDA Clearance To Recruit Teen Subjects Into Both Ongoing Netherton Syndrome Clinical Studies
Portfolio Pulse from Benzinga Newsdesk
Quoin Pharmaceuticals received FDA clearance to include teen patients in its Netherton Syndrome clinical studies, potentially expanding eligible subjects and expediting recruitment. This marks the first inclusion of non-adult subjects in such studies under an open Investigational New Drug Application.
March 04, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quoin Pharmaceuticals' FDA clearance to include teens in Netherton Syndrome studies could expedite recruitment and enhance data robustness.
The FDA clearance allows Quoin Pharmaceuticals to include a broader demographic in its clinical studies, which could lead to faster recruitment and potentially more comprehensive data. This development is significant as it's the first time non-adult subjects are included in Netherton Syndrome studies under an open IND, indicating a positive regulatory milestone for the company. The inclusion of a wider age range may also enhance the study's relevance and applicability, potentially improving the drug's profile and speeding up its development process.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90